Listed

Sensus Healthcare, Inc.: Form 10-Q for the period ended Mar 31, 2021

Filed with the SEC on May 14, 2021 and accepted by EDGAR at May 14, 2021, 12:19 ET.

Share

Management's discussion and analysis

As filed, 12,230 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

You should read the following discussion and analysis in conjunction with the information set forth within the financial statements and the notes thereto included elsewhere in this Quarterly Report on Form 10-Q, and with our Management’s Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the year ended December 31, 2020 (“Annual Report”).

Overview

Sensus Healthcare, Inc. (together, with its subsidiary, unless the context otherwise indicates, “Sensus” or the “Company”) is a medical device company committed to providing highly effective, non-invasive and cost-effective treatments for both oncological and non-oncological skin conditions. The Company uses a proprietary low-energy X-ray technology known as superficial radiation therapy (“SRT”), which is based on over a decade of dedicated research and development and has successfully incorporated SRT into a portfolio of treatment devices: the SRT-100TM, SRT-100+TM and SRT-100 VisionTM. To date, SRT technology has been used to effectively and safely treat oncological and non-oncological skin conditions in hundreds of thousands of patients around the world. With the introduction of Sculptura™, the Company has branched out into cancer treatment that goes far beyond skin and may provide a revolutionary treatment option for patients around the world.

Impact of COVID-19

The outbreak of COVID-19, which was declared a pandemic by the World Health Organization on March 11, 2020, has led to adverse impacts on the U.S. and global economies, as well as on the Company’s and its employees, operations, and customer demand. The Company has been able to continue to operate and service its customers throughout the pandemic. However, the pandemic significantly impacted the Company’s sales throughout 2020 and into 2021, as social distancing forced physicians to temporarily close their practices and could further impact the Company’s operations and the operations of the Company’s customers, suppliers and vendors as a result of ongoing quarantines, facility closures, and travel and logistics restrictions. The extent to which the COVID-19 pandemic impacts the Company’s business, results of operations and financial condition will depend on future developments. The Company cannot reasonably estimate the impact at this time. Sensus continues to service customers amid uncertainty and disruption linked to COVID-19 and is actively managing its business to respond to the impact.

Segment Information

The Company manages its business globally within one reportable segment, which is consistent with how our management reviews our business, prioritizes investment and resource allocation decisions and assesses operating performance.

Results of Operations

(in thousands)

For the Three Months Ended March 31, 2021 2020
Revenues $3,070 $1,679
Cost of sales 1,484 970
Gross profit 1,586 709
Operating expenses
Selling and marketing 1,068 1,791
General and administrative 972 1,330
Research and development 661 1,225
Total operating expenses 2,701 4,346
Loss from operations (1,115) (3,637)
Other income (expense)
Interest income - 50
Other income (expense), net - 50
Net Loss $(1,115) $(3,587)

Three months ended March 31, 2021 compared to the three months ended March 31, 2020

Revenues were $3.1 million for the three months ended March 31, 2021 compared to $1.7 million for the three months ended March 31, 2020, increased 82.8% or $1.4 million. The increase was primarily driven by the higher number of units sold in 2021, service revenue on installed units and the impact of COVID-19 in the first three months of 2020.

Cost of sales. Cost of sales was $1.5 million for the three months ended March 31, 2021 compared to $1.0 million for the three months ended March 31, 2020, an increase of $0.5 million, or 52.9%. The increase in cost of sales was commensurate with the increase in sales in the three months ended March 31, 2021.

Gross profit. Gross profit was $1.6 million for the three months ended March 31, 2021 compared to $0.7 million for the three months ended March 31, 2020, an increase of $0.9 million, or 123.8%. Our overall gross profit percentage was 51.6% in the three months ended March 31, 2021 compared to 42.2% in the corresponding period in 2020. The increase in gross profit was primarily driven by the higher number of units sold in 2021, service revenue on installed units and the impact of COVID-19 in the first three months of 2020.

Selling and marketing. Selling and marketing expense was $1.1 million for the three months ended March 31, 2021 compared to $1.8 million for the three months ended March 31, 2020, a decrease of $0.7 million, or 40.4%. The decrease was primarily attributable to a decrease in tradeshows expense due to cancellations related to COVID-19, reduced marketing activities including travel and salary and benefit expenses due to reduced headcount.

General and administrative. General and administrative expense was $1.0 million for the three months ended March 31, 2021 compared to $1.3 million for the three months ended March 31, 2020, a decrease of $0.3 million, or 26.9%. The net decrease in general and administrative expense was primarily due to salary and benefit expenses due to reduced headcount, partially offset by higher insurance premium costs.

Research and development. Research and development expense was $0.7 million for the three months ended March 31, 2021 compared to $1.2 million for the three months ended March 31, 2020, a decrease of $0.5 million, or 46.0%. The decrease in research and development spending reflected lower spending as the SculpturaTM project entered production phase during 2020.

Financial Condition

The Company’s cash, cash equivalent and investment balance decreased to $13.7 million at March 31, 2021 from $14.9 million at December 31, 2020, primarily due to cash used in operating activities including the timing of collections on the receivables for units sold in the first three months ended March 31, 2021.

There were no borrowings under the revolving line of credit at March 31, 2021 and December 31, 2020.

Liquidity and Capital Resources

The Company’s liquidity position and capital requirements may be impacted by a number of factors, including the following:

  • ability to generate and increase revenue;
  • fluctuations in gross margins, operating expenses and net results; and
  • fluctuations in working capital.

The Company’s primary short-term capital needs, which are subject to change, include expenditures related to:

  • expansion of sales and marketing activities; and
  • expansion of research and development activities.

Sensus’ management regularly evaluates cash requirements for current operations, commitments, capital requirements and business development transactions, and may seek to raise additional funds for these purposes in the future.

Cash flows

The following table provides a summary of our cash flows for the periods indicated:

(unaudited)

(in thousands)

Net Cash Provided by (Used In): For the Three Months Ended March 31, 2021 2020
Operating Activities $(1,115) $434
Investing Activities (80) 3,566
Financing Activities (60) (3)
Total $(1,255) $3,997

13

Net cash used in operating activities was $1.1 million for the three months ended March 31, 2021, consisting of a net loss of $1.1 million and a decrease in net operating assets of $0.3 million, partially offset by non-cash charges of $0.3 million. Cash flows used in operating activities primarily include the receipt of revenues offset by the payment of operating expenses incurred in the normal course of business, including year-end incentive compensation accrued for in the prior year. Net cash provided by operating activities was $0.4 million for the three months ended March 31, 2020, primarily due to the operating loss of $3.6 million, partially offset by a decrease in net operating assets of $3.7 million and by non-cash charges of $0.4 million.

Net cash used in investing activities for the three months ended March 31, 2021 reflected $0.1 million of purchases of property and equipment. Net cash provided by investing activities was $3.6 million, mostly due to matured investments during the three months ended March 31, 2020.

Net cash used in financing activities for the three months ended March 31, 2021 primarily reflected $0.1 million of loan repayments and withholding taxes on stock compensation.

Indebtedness

Please see Note 5, Debt, to the financial statements.

Contractual Obligations and Commitments

Please see Note 8, Commitments and Contingencies, to the financial statements.

Off-Balance Sheet Arrangements

The Company did not have during the periods presented, and does not currently have, any off-balance sheet arrangements.

Critical Accounting Policies and Estimates

The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenue and expense during the reporting periods. Actual results could differ significantly from those estimates. For a summary of these and additional accounting policies see Note 2, Significant Accounting Policies, in the notes to the condensed consolidated financial statements. In addition, see Critical Accounting Policies in Management’s Discussion and Analysis of Financial Condition and Results of Operations and Note 2, Significant Accounting Policies, in the 2020 Form 10-K for further information

JOBS Act

Sensus is an “emerging growth company,” as defined in the Jumpstart Our Business Startups Act. As such, the Company can take advantage of exemptions from various reporting requirements that are applicable to other public companies but not to “emerging growth companies,” including, but not limited to:

  • being permitted to provide only two years of audited financial statements, in addition to any required unaudited interim financial statements, with correspondingly reduced “Management’s Discussion and Analysis of Financial Condition and Results of Operations” disclosure;
  • not being required to comply with the auditor attestation requirements in the assessment of the Company’s internal control over financial reporting under Section 404 of the Sarbanes-Oxley Act;
  • reduced disclosure obligations regarding executive compensation in the Company’s periodic reports and proxy statements; and
  • exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.

Sensus is expected to remain an emerging growth company until December 31, 2021, following which it is expected to continue to be a “smaller reporting company,” which will enable it to continue to take advantage of many of these exemptions, as discussed below. Investors may find Sensus’ common stock less attractive if the Company chooses to rely on these exemptions. If some investors find Sensus’ common stock less attractive as a result of any choices to reduce future disclosure, there may be a less active trading market for the Company’s common stock and the price of its common stock may be more volatile.

In addition, an emerging growth company can delay its adoption of certain accounting standards until those standards would otherwise apply to private companies. However, the Company has chosen to “opt out” of such extended transition period, and as a result, plans to comply with any new or revised accounting standards on the relevant dates on which non-emerging growth companies must adopt such standards. Section 107 of the JOBS Act provides that the decision to opt out of the extended transition period for complying with new or revised accounting standards is irrevocable.

Controls and procedures

As filed, 919 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Evaluation of Disclosure Control and Procedures

As of March 31, 2021, the end of the period covered by this Form 10-Q, our management, including our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934). Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer each concluded that, as of March 31, 2021, the end of the period covered by this Form 10-Q, we maintained effective disclosure controls and procedures.

Changes in Internal Control over Financial Reporting

There have been no significant changes in our internal control over financial reporting during our most recently completed fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Risk factors

As filed, 577 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

In addition to the other information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the factors discussed in Part I, Item 1A. “Risk Factors” in our Annual Report on Form 10-K, as updated in our subsequent quarterly reports. The risks described in our Annual Report on Form 10-K and our subsequent quarterly reports are not the only risks facing us. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition or operating results.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2021-03-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2021-01-01 to 2021-03-31$3.1mus-gaap:Revenues
Cost of revenue3 months2021-01-01 to 2021-03-31$1.5mus-gaap:CostOfGoodsAndServicesSold
Gross profit3 months2021-01-01 to 2021-03-31$1.6mus-gaap:GrossProfit
Research and development3 months2021-01-01 to 2021-03-31$661.0kus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2021-01-01 to 2021-03-31−$1.1mus-gaap:OperatingIncomeLoss
Income tax3 months2021-01-01 to 2021-03-31$0us-gaap:IncomeTaxExpenseBenefit
Net income3 months2021-01-01 to 2021-03-31−$1.1mus-gaap:NetIncomeLoss
Operating cash flow3 months2021-01-01 to 2021-03-31−$1.1mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure3 months2021-01-01 to 2021-03-31$80.0kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2021-03-31$13.7mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2021-03-31$23.9mus-gaap:AssetsCurrent
Total assetsAt period end2021-03-31$26.5mus-gaap:Assets
Current liabilitiesAt period end2021-03-31$4.7mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2021-03-31$6.0mus-gaap:Liabilities
Shareholders' equityAt period end2021-03-31$20.4mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001213900-21-026314. Last ingested by Listed: Nov 14, 2026, 13:10 ET. Listed shows no prices and gives no investment advice.